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Mobile Health (m-Mealth) for diabetes management 
Robert SH Istepanian, Donatella Casiglia, John W Gregory 
  
ABSTRACT 
Diabetes is a major health challenge with a global impact regardless of age, country or economic 
condition. The increased prevalence of diabetes is reaching alarming levels. The necessity and urgency 
to find innovative care delivery solutions is becoming more important, particularly in the digital age. 
It is expected in the near future that more people with diabetes, especially the younger generations 
will be empowered by their smartphones and relevant mobile health (m-Health) innovations, to take 
more responsibility of their condition. Clinicians and healthcare providers are increasingly likely to 
assuŵe the ƌole of ͚Ŷaǀigatoƌs͛ aŶd ͚adǀisoƌs͛ ƌatheƌ thaŶ siŵply the ŵediĐal gatekeepeƌ foƌ theiƌ 
patients. In this article, we describe the general architecture of current m-Health systems and 
applications for diabetes management. We also discuss the clinical evidence for impact from these 
important and innovative approaches to diabetes self-care and management and likely future trends 
in their usage. The latest statistiĐs iŶdiĐate that theƌe aƌe ŵoƌe thaŶ ϭϮϬϬ diaďetes sŵaƌtphoŶe ͚apps͛ 
and this area is growing exponentially in terms of ideas, technologies, devices and the associated 
industry. M-Health for diabetes care is now a major business stream for the medical device, mobile 
phone and IT telecommunication industries with high expectations arising from the potential benefits 
to be gained by both patients and healthcare providers. However, this potential has not yet been fully 
developed on the clinical side. This may be due to many factors including the reluctance of clinicians 
to engage with these technologies due to the lack of clinical evidence for their efficacy, poor 
adherence of people with diabetes to longterm use of these apps and the reluctance of healthcare 
funders to reimburse mobile diabetes. 
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 Diabetes mellitus is a major global chronic disease that affects an estimated 415 million adults globally. 
With an additional 318 million adults with impaired glucose tolerance, they are at high risk of 
developing comorbidity in the future, including heart disease, end-stage renal failure and the single 
biggest cause of preventable blindness, as well as other causes of premature mortality (International 
Diabetes Federation, 2015). 
The economic burden of diabetes is increasing globally, both in developing and developed countries. 
These alarming statistics represent major opportunities—but also challenges—for mobile health (m-
Health) systems designed and developed for not only the management of but also the prediction of 
diabetes in different healthcare delivery settings. 
Figure. 1 Impact of intensive therapy of major diabetes RCT and summary of complications (adapted 
from Inzucchi et al, 2015 
In clinical terms, diabetes is associated with risk of long term complications (Inzucchi et al, 2015). The 
most common macrovascular complications include coronary artery disease and cerebrovascular 
disease, while for the microvascular complications, retinopathy, neuropathy and chronic kidney 
disease are the most common. These complications result from metabolic abnormalities, including 
hyperglycemia, elevated levels of free fatty acids, and insulin resistance.  
Figure 1 summarises the outcomes of major randomised controlled trials (RCTs) as published by the 
American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 
(Inzucchi et al, 2015). These results indicated that intensive glycemic control in both type 1 (T1D) and 
type 2 (T2D) diabetes prevents or delays microvascular complications, specifically retinopathy and 
albuminuria. However, the data from these trials concerning the glucose control and macrovascular 
complications were more complex and overall neutral (Inzucchi et al, 2015).  
To alleviate these uncertainties and provide further evidence on the role of m-Health technologies to 
reduce complications, the concept of mobile diabetes self-management has become an important 
element of diabetes care in recent years (Istepanian and Woodward, 2017). For more than two 
decades, many innovative mobile health approaches for promoting diabetes self-care have been 
increasingly adopted including: 
• Providing support for self-management strategies, especially in T2D 
• Use of new m-Health technological approaches for better patient education enabling new 
integrated diabetes care models that embrace these new technological developments and solutions 
(Istepanian and Woodward, 2017). 
Over the last decade or so, clinicians and users have become confused about the differences between 
the four pillars of IT for healthcare (telemedicine, telehealth, e-health and m-Health)and how these 
might be applied to diabetes care (Istepanian and Woodward, 2017). During this period, numerous 
studies of telehealth and telemedicine were conducted evaluating the clinical effectiveness and 
impact of these systems for diabetes management (Istepanian, 2015). However, overall these studies 
provided conflicting evidence for the clinicaland cost-effectiveness of these approaches. Since 2007, 
diabetes management using smartphone technologies has become one of the most prolific areas of 
m-Health research and development. This is reflected in numerous pilot studies and the proliferation 
of hundreds of commercial diabetes apps and mobile self-management systems (Istepanian, 2015; 
Istepanian and Woodward, 2017). However, this commercial interest has not yet translated to clinical 
practice. This may be due to many factors, including reluctance of clinicians to engage in the use of 
such technologies due to their perception of a lack of clinical evidence for benefit; the poor adherence 
of people with diabetes to the long-term use of apps; and the reluctance of commissioners of 
healthcare to reimburse mobile diabetes solutions. This can be attributed to several factors such as 
the diversity of the existing economic and service reimbursement models. These are mostly based on 
the USA healthcare model of m-Health ƌeiŵďuƌseŵeŶt ͚ďy the yaƌd͛ ďilliŶg appƌoaĐh. These ŵodels 
clearly are inapplicable to low resource settings and require more frugal approaches. Further, there is 
no clear regulatory framework for m-Health in diabetes, considering the potential impact of these 
systems globally. 
From the clinical perspective, these pilot studies have indicated promising but uncertain outcomes, 
especially with respect to improving blood glucose control (glycosylated haemoglobin (HbA1c)) until 
more recently (Istepanian and Woodward, 2017). Although there is a major global market for the 
potential integration of m-Health into diabetes care, there is no largescale or definitive long-term 
study—either planned or implemented—to validate the clinical effectiveness of these technologies 
and their impact on diabetes self-care and management. 
m-Health for diabetes self-management 
The use of smartphones for diabetes self management has seen massive interest in the last decade, 
since the inception of the first smart phone in 2007. In the last decade several RCTs been conducted 
to provide the necessary clinical evidence for the validity of this approach to diabetes care. Although 
results from these trials have produced outcomes with uncertain clinical implications, there is 
increasing evidence and consensus that these technologies and their associated smartphone apps can 
be an effective approach and a supplementary support to standard diabetes self-management. 
However, much research remains to be undertaken in this area to provide better clinical evidence for 
the potential benefits arising from this technology— particularly in parts of the world with poor 
resources, where the prevalence of diabetes is high. 
The infrastructure that underpins m-Health for diabetes self-management is shown in Figure 2 
(Istepanian and Woodward, 2017). The basic functions of a smartphone-based diabetes 
selfmanagement system adhere to the following principles: 
• To empower people with diabetes to self-monitor blood glucose (SMBG) or other variables 
when and as needed (e.g. blood pressure, weight, and diet) 
• To engage people in the management of their diabetes by promoting self-efficacy 
• To achieve pre-set care targets and to provide interactive feedback between patients and 
physicians with respect to disease progress and adherence to therapy 
• To allow physicians to facilitate patient self-care, to improve outcomes with potential cost 
savings (Istepanian and Woodward, 2017). 
This intervention and architecture consist of three basic modules: mobile patient end; healthcare 
provider or clinician end; and remote data servers or clouds, which host the patient electronic health 
record (EHR), together with data analytics, inference engine files (for artificial intelligence) and system 
ĐoŶtƌolleƌs. These seƌǀeƌs aƌe usually hosted iŶ seĐuƌe loĐatioŶs. The ŵoďile patieŶt aŶd physiĐiaŶ͛s 
ends are usually connected via the mobile network or other internet connectivity channels (e.g. WiFi) 
to transfer the blood glucose readings (and other data such as about diet and exercise) to the remote 
server for further processing and feedback. A brief summary of these functions is described next for 
completeness. Further details on the technical development of these systems are described elsewhere 
(Istepanian and Woodward, 2017). 
As shown in Figure 2, the general architecture of m-Health diabetes self-management and care 
systems consist of the following modules: 
  
Figure 2. General architecture of m-Health diabetes self-management and care system (adapted  
• The patient end, which consists of a smartphone equipped with a special diabetes app 
connected wirelessly via Bluetooth to a blood glucose meter and used for tracking and storing the 
patieŶt͛s daily ďlood gluĐose data aŶd status. HypeƌteŶsiǀe iŶdiǀiduals ǁith diaďetes ŵay also ďe giǀeŶ 
a wireless blood pressure device and weight scales as required. From   Istepanian and Woodward, 
2017)  The patient is then required to complete basic training and an educational programme on using 
these systems 
• The aĐƋuiƌed ďlood gluĐose data aƌe usually tƌaŶsŵitted ǁiƌelessly ǀia the iŶdiǀidual patieŶt͛s 
smart phone and stored in a remote portal hosted in a health clinic or hospital. This portal consists of 
the patieŶt͛s EH‘, suppoƌted ǁith iŶtelligeŶt data aŶalytiĐ tools that ĐaŶ pƌoĐess the data aŶd pƌoduĐe 
simple illustrative graphics. These can be accessed and viewed by the patient and physician via two 
separate web portals, each designed and developed for separate access. The graphics provide 
information and decision support messages, such as lifestyle change, educational notes, and 
ŵediĐatioŶ ƌeƋuiƌed to iŵpƌoǀe the patieŶt͛s daily ŵaŶageŵeŶt ƌoutiŶe  
• The adaptation of any medication and treatment plans required for individual patients. This is 
based on their selfmanagement history, daily blood glucose profiles, treatment progress, and 
designated therapy protocol plans assessed regularly at 3–6 month follow-up intervals. 
The schedule and frequency of taking daily blood glucose readings and other medical data are 
dependent on the individual care plan made for each patient by their specialist and based on their 
individual diabetes type, treatment and progress. The timings of these readings are usually 
pƌogƌaŵŵed iŶ the patieŶt͛s sŵaƌtphoŶe app as ƌeŵiŶdeƌs to take ƌeadiŶgs aĐĐoƌdiŶg to pƌe-set 
schedules. 
Smart devices, such as continuous glucose monitors and continuous subcutaneous insulin infusion 
pumps used by people with T1D can also communicate wirelessly to their smartphones for monitoring 
purposes. Patients are usually required to test their blood glucose concentrations several times daily, 
usually before meals and 2–4 hours after meals. It is likely that new generations of wireless diabetes 
monitoring products will be increasingly available in the near future.  
The patient empowerment process is embodied by these systems in many aspects, allowing them to 
view variations in their blood glucose levels on their mobile phones—daily, weekly or as needed. Apps 
with specific software are programmed to alert patients to their lifestyle and treatment choices, as 
well as helping them to monitor for potential hypoglycaemic or hyperglycaemic episodes. In some 
apps it is possible to track average glycemia for real-time estimation of HbA1c levels derived from 
SMBG data. It must be emphasised that there are many efficacy, safety and regulatory challenges 
associated with apps developed for mobile diabetes selfmanagement (Istepanian, 2015). 
Recent reviews of the use of smartphone apps for diabetes care indicate the majority of these apps 
focus on health tracking (e.g. blood glucose, insulin dose and carbohydrate intake), requiring manual 
entry of the blood glucose measurement and relevant health data. More recent developments in 
newer blood glucose meters allow the automatic transmission of the blood glucose data and 
measurements to be transferred to an app using seamless wireless Bluetooth connectivity (Istepanian 
and Woodward. 2017). However, the interoperability of the different blood glucose devices with 
different smartphone operating systems, in addition to their incompatibility of connecting different 
blood glucose meters with a unified web-based platforms, is still an ongoing challenge. 
Clinical effectiveness of m-Health interventions 
The prevention of hypoglycemic episodes has been identified as an important objective in diabetes 
management with SMBG. It has been increasingly proven to provide better diabetes management and 
prevention of both acute and chronic complications of diabetes, particularly for self-regulatory 
prevention of significant hypoglycemic episodes (Schutt et al, 2006; Garg and Hirsch, 2015). Although 
the value of SMBG for those with T2D remains debatable, continuous glucose monitoring is approved 
as an adjunct to SMBG (Garg and Hirsch, 2015). 
The patient representative charity Diabetes UK recommends that SMBG be advised in people receiving 
sulphonylurea and prandial glucose regulatory therapies because of the risk of hypoglycemia in these 
groups (Diabetes UK, 2013). By contrast, the role of SMBG in self-management of those with T1D is 
less controversial, and the literature generally supports SMBG to achieve better glucose control in T1D 
(Garg and Hirsch, 2015). From the clinical perspective, the results of a large multicentre study including 
24 500 patients from 191 centres in Germany and Australia showed that frequent SMBG is associated 
with better metabolic control in both those with T1D and T2D (Schutt et al, 2006).  
More recently, there has been an increase in the numbers of published clinical pilot studies and formal 
RCTs to evaluate different mobile platforms for the management of T1D, T2D, and gestational diabetes 
(Istepanian and Woodward, 2017). These and more recent reviews provide a clearer picture of the 
clinical evidence that these technologies may be effective in supporting diabetes care and self-
management (Liang et al, 2011; Hou et al, 2016; Cui et al, 2016). A metaanalysis of 22 trials conducted 
between 2005 and 2009 with a total of 1657 participants showed that mobile phone interventions 
reduced HbA1c levels by a mean of 0.5% (6 mmol/mol; 95% confidence interval, 0.3–0.7% (4–8 
mmol/mol)) over a median of 6 months follow-up duration, A further sub-group analysis of 11 studies 
among those with T2D showed reductions in HbA1c that were more significant compared to studies 
in those with T1D (0.8% (9 mmol/mol) and 0.3% (3 mmol/ mol) respectively; p = 0.02) (Liang et al, 
2011).  
Another recent review and meta-analysis analysed the outcomes of 14 clinical RCTs in both T1D and 
T2D (n = 1360) (Hou et al, 2016). This study concluded that all the T2D studies reported reductions in 
HbA1c levels with a mean reduction using the mobile phone app compared to the control groups of 
0.49%. It particularly noted that younger patients were most likely to benefit from the use of the m-
Health and apps compared to other age groups. However, this review found inadequate data to 
support the effectiveness of the app interventions for T1D patients with no statistically significant 
beneficial outcomes in trials comparing HbA1c between m-Health apps and intervention groups (Hou 
et al, 2016).  
Another recent meta-analysis of mobile health interventions for those with T2D in 13 studies with a 
total of 1022 patients concluded that m-Health app-based self-management shows moderate benefits 
on blood glucose control with a pooled effect on HbA1c reduction of -0.40% (-4.37 mmol/mol) (Liang 
et al, 2011). From these two recent meta-analyses, it seems that there are significant benefits to 
controlling blood glucose levels arising from use of m-Health apps, especially in those with T2D using 
oral medication or in the context of their lifestyle behaviour. 
Recent studies have also shown that mobile short message service (SMS) interventions (text 
ŵessagiŶg͛Ϳ, ĐaŶ pƌoǀide a siŵple yet effeĐtiǀe appƌoaĐh foƌ iŵpƌoǀiŶg eduĐatioŶ aŶd ĐoŵŵuŶiĐatioŶ 
for people with diabetes. Several RCTs and pilot studies of SMS interventions to support diabetes self-
management have been conducted in different countries (Haddad et al, 2014; Hall et al, 2015). The 
clinical outcomes from these SMS studies provide preliminary evidence to suggest the clinical impact 
and effectiveness of mobile SMS interventions in improving diabetes care outcomes but further 
studies are required.  
Discussion 
There is increasing evidence of the clinical impact and cost-effectiveness of m-Health and smartphone-
centric approaches for diabetes care. However, there are unmet needs for diabetes care especially in 
T2D for which m-Health interventions, if designed and developed correctly, may provide better 
outcomes.   
These include: 
• The increasing requirement for practical approaches to prevention of onset of diabetes 
through screening for pre-diabetes 
• The need for more innovative approaches to achieving better HbA1c targets 
• The need for better prevention of disease progression and complications 
• The need to improve patient adherence 
• The requirement to support dietetic education for patients. 
However, there are several barriers to this approach that can be generally categorised from the 
patieŶt aŶd Đaƌe pƌoǀideƌ͛s peƌspeĐtiǀes. These iŶĐlude soĐioeĐoŶoŵiĐ, psyĐhosoĐial, physiĐal aŶd 
environmental factors that may be perceived by individuals to influence their ability to perform 
adequate self-care activities. For the healthcare provider, these barriers relate primarily to cost, 
privacy, security, cultural and policy issues (Istepanian and Woodward, 2017).  
From the business perspective, it is estimated that there are currently more that1200 diabetes smart 
apps in the market (Istepanian and Woodward, 2017). This trend is likely to increase, with the 
possiďility of the eŵeƌgeŶĐe of the ͚diaďetes apps pƌesĐƌiptioŶs͛ Đultuƌe dƌiǀeŶ ďy the ŵaƌket push iŶ 
this area. Most of these commercial diabetes apps available in the market today are designed and 
developed for narrow segments of the market with specific tasks and few supplemented with clinical 
or pilot studies.  
Furthermore, with most of these apps, the role of the healthcare provider is missing, with most 
deǀeloped as tools aĐtiŶg as eleĐtƌoŶiĐ logďooks foƌ the patieŶt͛s ďlood gluĐose ŵoŶitoƌiŶg leǀels. 
Moreover, few of these offer effective intelligent coaching and behavioural self-management 
functionalities that can provide much better and long-term management and usability mechanisms 
(Diabetes UK, 2013). Most of the current re-imbursement models for mobile diabetes care are 
developed in the USA and are unlikely to be applied in low resource countries where their healthcare 
delivery provisions and economic models are different. 
There are also many clinical uncertainties associated with the m-Health interventions for diabetes self-
management. These can be summarised as follows: 
• There is increasing debate on the clinical effectiveness of mobile SMBG interventions, 
supplemented by a lack of large clinically robust m-Health studies and RCTs in this area. Adequately 
powered, well-designed studies are much needed to evaluate their clinical effectiveness. Those 
studies that have been published evaluated the effect of the intervention on primary outcomes, such 
as HbA1c, body mass index, weight and blood pressure. Such studies should also measure the effect 
on secondary outcomes, e.g. impact on lifestyle change, long-term usability and adherence, social and 
behavioural change, care barriers and cost effectiveness 
• There are so far no detailed clinical studies of the impact of mobile phone interventions on 
obese individuals with diabetes (so-Đalled ͚diaďesity͛Ϳ 
• Identification of suitable smart m-Health educational models that translate the standards of 
diabetes care into protocols suitable for different ethnic or resource settings 
• The role of incentives in facilitating behavioural change by appropriate smart educational 
tools is not yet well understood or fully realised 
• The challenges of cyber-security and privacy concerns and the ownership of large health data 
sets generated by social networking and apps 
• The development of alternative business models and ecosystems for creating a new 
generation of m-Health diabetes care models. These might be based on recent technological advances 
and not solely based on smartphonecentric care models (Istepanian and Woodward, 2017). 
Conclusion  
In recent years there has been increasing interest in developing m-Health approaches for diabetes 
self-care and management. These are usually referred to as smartphone-based diabetes self 
ŵaŶageŵeŶt oƌ ͚digital diaďetes͛. Although the sŵaƌtphoŶe app ďusiŶess aŶd suppoƌtiŶg iŶdustƌy 
have been much-hyped, there has not been the equivalent development of clinical evidence to back 
the use of this technology.  
It seems very likely that these technologies will become the norm in diabetes self care in the near 
future. However, to achieve this goal, more clinical studies focusing on the most effective outcomes 
that may impact the health and wellbeing of individuals with diabetes are needed. The use of these 
m-Health technologies for diabetes should also be applied to individuals with diabetes in the 
developing world, where their impact may be greater due to the resource challenges of delivering 
high-quality care. The need to develop more frugal m-Health methods for diabetes care that are 
affordable, correctly aligned to the economic environment, and better tailored to the social and 
cultural requirements of patients in these areas is vital for the future success of these technologies in 
this important area. This is crucial for widening the usage spectrum and the role of mobile health for 
diabetes care, especially iŶ loǁ iŶĐoŵe aŶd loǁ ƌesouƌĐe ĐouŶtƌies ďeyoŶd the ĐuƌƌeŶt ͚tƌaditioŶal͛ 
smartphone-centric models.  
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